212
Participants
Start Date
March 1, 2022
Primary Completion Date
April 25, 2025
Study Completion Date
April 25, 2025
Fractionated CO2-laser
All women will be undergoing FxCO2-laser therapy as this treatment is a criterion for enrollment.
Clobetasol Propionate 0.05% Ointment
Clobetasol propionate 0.05% ointment obtained from a commercial manufacturer
Columbia University, New York
The Institute for Female Pelvic Medicine & Reconstructive Surgery, Allentown
MedStar Health, Washington D.C.
Walter Reed National Military Medical Center, Bethesda
Ohio State University, Columbus
Waukesha Memorial Hospital, Waukesha
University of Chicago, Chicago
The University of New Mexico, Albuquerque
Kaiser Permanente - Southern California Permanente Medical Group, San Diego
Massachusetts General Hospital, Boston
Lead Sponsor
Patty Brisben Foundation For Women's Sexual Health
OTHER
Society of Gynecologic Surgeons
UNKNOWN
Medstar Health Research Institute
OTHER